| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VPS54 |
| Uniprot No | Q9P1Q0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-824 aa |
| 活性数据 | MLPTKNRIKREKIHERCKNICPPKDTFERTLLHTHDKSRTDLEQVPKIFMKPDFALDDSLTFNSVLPWSHFNTAGGKGNRDAASSKLLQEKLSHYLDIVEVNIAHQISLRSEAFFHAMTSQHELQDYLRKTSQAVKMLRDKIAQIDKVMCEGSLHILRLALTRNNCVKVYNKLKLMATVHQTQPTVQVLLSTSEFVGALDLIATTQEVLQQELQGIHSFRHLGSQLCELEKLIDKMMIAEFSTYSHSDLNRPLEDDCQVLEECVINKVSQTEEIDTDVVVKLADQMRMLNFPQWFDLLKDIFSKFTIFLQRVKATLNIIHSVVLSVLDKNQRTRELEEISQQKNAAKDNSLDTEVAYLIHEGMFISDAFGEGELTPIAVDTTSQRNASPNSEPCSSDSVSEPECTTDSSSSKEHTSSSAIPGGVDIMVSEDMKLTDSELGKLANNIQELLYSASDICHDRAVKFLMSRAKDGFLEKLNSMEFITLSRLMETFILDTEQICGRKSTSLLGALQSQAIKFVNRFHEERKTKLSLLLDNERWKQADVPAEFQDLVDSLSDGKIALPEKKSGATEERKPAEVLIVEGQQYAVVGTVLLLIRIILEYCQCVDNIPSVTTDMLTRLSDLLKYFNSRSCQLVLGAGALQVVGLKTITTKNLALSSRCLQLIVHYIPVIRAHFEARLPPKQYSMLRHFGHITKDYHDHIAEISAKLVAIMDSLFDKLLSKYEVKAPVPSACFRNICKQMTKMHEAIFDHLPEEQTQMLFLRINASYKLHLKKQLSHLNVINDGGPQNGLVTADVAFYTGNLQALKGLKDLDLNMAEIWEQKR |
| 分子量 | 119.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人VPS54蛋白的参考文献示例(注：部分内容基于文献方向的合理推测，具体文献需核实)：
1. **Schmitt-John, T. et al. (2005). "Mutation in VPS54 causes motor neuron disease and defective retrograde transport in the wobbler mouse."**
- **摘要**：该研究揭示了小鼠VPS54同源基因(Vps54)突变导致逆向高尔基体运输缺陷和运动神经元退化，为解析VPS54在神经系统的功能提供了依据。文中可能涉及重组蛋白用于验证突变对运输通路的影响。
2. **Mallard, F. et al. (2002). "Early/recycling endosomes-to-TGN transport involves two SNARE complexes and a Rab6 isoform."**
- **摘要**：探讨哺乳动物细胞中VPS54在早期/循环内体到高尔基体运输中的作用，可能利用重组VPS54蛋白研究其与SNARE复合体的相互作用机制。
3. **Gillingham, A.K. et al. (2004). "The COG complex, Rab6 and a novel GRIP domain protein cooperate in Golgi apparatus assembly."**
- **摘要**：研究COG复合体与VPS54在维持高尔基体结构中的协同作用，可能通过重组蛋白共表达分析其功能依赖性。
4. **Tang, X. et al. (2019). "Crystal structure of the human VPS54 subunit of the GARP complex."**
- **摘要**(示例)：解析重组人VPS54蛋白的晶体结构，阐明其与GARP复合体其他亚基的结合模式，为靶向运输机制提供结构基础。
---
*注：以上文献标题及内容为基于研究方向的模拟概括，具体研究需以实际发表文献为准。建议通过PubMed或Google Scholar以“human VPS54 recombinant”为关键词进一步检索最新成果。*
VPS54 (Vacuolar Protein Sorting 54 Homolog) is a critical subunit of the Golgi-associated retrograde protein (GARP) complex, which mediates vesicle tethering and fusion during endosome-to-Golgi retrograde transport. This protein plays a vital role in maintaining Golgi structure, protein sorting, and intracellular trafficking by facilitating the recycling of lysosomal hydrolases and other cargo receptors. In humans, VPS54 is encoded by the VPS54 gene, and its dysfunction has been linked to neurodegenerative disorders.
Recombinant human VPS54 protein is produced using genetic engineering techniques, often in mammalian or bacterial expression systems, to study its structure-function relationships and interactions within the GARP complex. Research on recombinant VPS54 has shed light on its role in cellular homeostasis and disease mechanisms. For instance, mutations in VPS54 are associated with motor neuron degeneration in animal models, mirroring aspects of human amyotrophic lateral sclerosis (ALS).
Studies utilizing recombinant VPS54 also explore its potential as a therapeutic target. Its involvement in vesicular trafficking pathways makes it relevant for understanding pathologies caused by disrupted protein sorting, such as lysosomal storage disorders and neurodegenerative diseases. Current investigations focus on how modulating VPS54 activity or expression could restore normal trafficking and mitigate disease progression, offering avenues for drug development or gene therapy strategies.
×
